According to Xu et al., who reported TP53 mutations in 88% of NSCLC EGFR-mutated patients that responded for <6 months to an EGFR TKIs, with respect to 13% of responders for >24 months [29], our results show a higher rate of TP53 mutations in non-responders group, with no TP53 mutated patients in the long responder group. Here, EGFR is linked to non-small cell lung carcinoma.